y 27632 has been researched along with cvt 313 in 2 studies
Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (cvt 313) | Trials (cvt 313) | Recent Studies (post-2010) (cvt 313) |
---|---|---|---|---|---|
1,924 | 3 | 891 | 19 | 0 | 11 |
Protein | Taxonomy | y 27632 (IC50) | cvt 313 (IC50) |
---|---|---|---|
Cyclin-T1 | Homo sapiens (human) | 2.3 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 3.7 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 3.7 | |
Cyclin-A2 | Homo sapiens (human) | 0.22 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.176 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.198 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 9.2 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 2.3 | |
Cyclin-H | Homo sapiens (human) | 9.2 | |
CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 9.2 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.419 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.419 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
2 other study(ies) available for y 27632 and cvt 313
Article | Year |
---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |